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SUMMARY
Measles surveillance data in Blantyre, Malawi were reviewed for 1996–8 to describe the
epidemiology of infection and to estimate vaccine efficacy (VE) by the screening method. A
total of 674 measles cases were reported to the Blantyre District Health Office during this
period. Age distribution showed that 108 (16–1%) of the cases were aged less than 1 year. The
median age was 5 years. Eighty percent of the cases between 1 and 19 years had been
previously vaccinated. VE was 68–6% (95% CI, 52–7–79–2) for children 12–23 months of age
and 67–3% (95% CI, 48–3–79–3) for infants 9–11 months of age. Reasons for this low vaccine
efficacy are discussed. Previous vaccination history was negatively associated with the risk for
developing cough during measles infection (odds ratio (OR), 0–30; 95% CI, 0–09–0–91),
diarrhoea (OR, 0–64; CI, 0–44–0–95) and pneumonia (OR, 0–40; CI, 0–25–0–62). Logistic
regression analysis showed that pneumonia in adults was negatively associated with vaccination
history. The passive surveillance system for measles in Malawi was useful to describe the
epidemiology of measles.
INTRODUCTION
Measles has been a killer disease throughout human
history. Although the Expanded Programme on
Immunization (EPI) has been operating since 1974,
measles still causes 31 million cases and one million
deaths annually in the world [1]. Most of these cases
occur in developing countries. In Malawi, measles was
reported as the third cause (20–6%) of mortality in the
second year of life [2], although measles vaccination
coverage was high as shown in Figure 1. Although the
incidence of measles in Malawi has dropped dra-
matically since 1993, several thousand measles cases
were still reported annually until the mass measles
* Author for correspondence: Tropical Child Health Group,
Liverpool School of Tropical Medicine, Pembroke Place, Liverpool
L3 5QA, UK.
vaccination campaign took place in October 1998 [3].
The reason why measles had been prevalent despite
the high vaccination coverage in Malawi in mid-1990s
is worth considering. One of the possible explanations
is a falsely high estimate of vaccination coverage. The
other is low vaccine efficacy (VE). In Malawi, measles
vaccine is given after 9 months of age as in other
developing countries. It has been reported that
measles VE was 95% at 9 months in Niger [4], and
more than 90% in Mozambican refugee camps in
Malawi [5]. However, measles accounted for 10–4% of
hospital admissions (the fourth cause), and 8–7% of
in-patient mortality (the fifth cause) in children under
5 years in 1992 [6]. These statistics for measles cases
were high in view of a reported 80–90% vaccination
coverage. Therefore, it is important to confirm that
measles vaccination coverage and VE in Malawi was
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Fig. 1. Measles vaccination coverage and number of reported cases in Malawi. Line, measles vaccination coverage; bars,
number of cases (incidence data before 1990 were not available). (Source: Malawi EPI Unit.)
actually as high as reported and comparable with
reported efficacy. This study was carried out to
describe the epidemiology of measles in Blantyre
District, Malawi where Blantyre, the most thriving
city in the country, is located. A further aim was to
calculate measles VE by the screening method in view
of the significant reported morbidity and mortality
despite good vaccination coverage.
METHODS
This study reviewed measles case records in Blantyre
District, Malawi for the 3-year period 1996–8. The
population in Blantyre District was 782226 in 1998,
39% of whom lived in rural areas [7]. This proportion
is lower than the national average of 89%, because
Blantyre is the most thriving city in Malawi and the
district is relatively well developed. Measles Outbreak
Investigation Forms (MOIF) used for reporting
measles cases by health centres and hospitals to the
Blantyre District Health Office (DHO) were reviewed.
This form collects information on the name, age,
village, date of onset of rash, vaccination history, age
(month) at vaccination, presence of cough, runny
nose, red eyes, diarrhoea, pneumonia, and death for
each measles case.
In Malawi, measles has been diagnosed by health
facility staff according to the standard case definition
of the WHO [8], which is ‘Any person with:
generalized maculopapular rash and a history of fever
of 38 °C or more and at least one of the following:
cough, runny nose or conjunctivitis ; or any person in
whom a health professional suspects measles. ’ Aaby
et al. reported that measles has been feared in the
community in Guinea–Bissau and there was good
correspondence between parental diagnoses and clini-
cal records and with serological surveys [9]. Because
measles has also been prevalent and feared in Malawi,
we believe that diagnoses of measles by the health
facility staff in Blantyre District were reasonably
reliable. MOIF were reported when more than five
measles cases occurred in a week at each health facility
in the entire district. Therefore if less than five cases
occurred in 1 week at a site, those cases were not
usually reported to the DHO and not included in this
study. However, several health facilities have reported
measles cases when less than this cut-off.
The data were analysed with Epi-Info version 6.0
(Centers for Disease Control and Prevention, Atlanta,
GA, USA) and StatView version 5 (SAS Institute Inc.
Cary, NC, USA). Proportions were compared using
the v# test or Fisher’s exact test. The Mann–Whitney
U test was used to compare the median of a variable
for non-normally distributed data. Multiple logistic
regression analysis was used to compare clinical
symptoms by stratified age groups with adjustment
for possible confounding. The Edwards test, which fits
a sine curve to monthly incidence data, was used to
assess the epidemic pattern of measles [10]. Measles
VE was calculated by the screening method [11]. It has
been reported by an active surveillance in Malawi that
measles vaccination coverage was 67–9% in infants
and 88–3% in children 12–23 months of age in 1996
[12]. Age-stratified vaccination coverage was only
available for these two age groups. Other coverage
data available were based on the ordinary EPI reports,
which estimate coverage by dividing the number of
vaccine doses used by the size of target population.
Because such figures may not have been sufficiently
accurate, we used the coverage data from active
surveillance only. The percentage of cases vaccinated
(PCV) was derived from the case record review.
RESULTS
Descriptive epidemiology
A total of 674 measles cases were reported to the
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Fig. 2. Age distribution of measles cases. Three cases whose ages were unknown were excluded.
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Fig. 3. Age distribution of measles cases in infants.
Blantyre DHO during the 3-year period. The age
distribution of the cases is shown in Figure 2. Measles
occurred most frequently in children below 2 years of
age: 108 (16–1%) cases were less than 1 year, and 55
(8–2%) less than 9 months old. The median age was 5
years. There was an even distribution for children
between 2 and 12 years. Twenty-five (3–7%) cases
occurred in adults older than 19 years of age. The
male to female ratio was 1–09. Figure 3 shows the age
distribution in infants. Fifty-one percent of infants
were less than 9 months, 34% between 6 and 8
months.
The monthly distribution of measles cases is shown
in Figure 4. We defined an epidemic as the period of
high measles incidence which is spaced by more than
3 months of very low incidence (! 5 cases}month).
The first and the third epidemics had their peaks on 27
April and 28 June, respectively (Edwards test) [10].
The peak of the second epidemic was on 30 October.
This minor epidemic had a shorter epidemic period of
4 months. These annual peaks were all highly sig-
nificant when tested for seasonal variation (P! 0–001,
Edwards test).
Figure 5 shows the annual incidence of measles by
age group. The population for each age group in 1997
and 1996 was extrapolated from the 1998 census data
using a 2–6% annual growth rate in Blantyre District
[7]. Annual incidence of measles for each age group
was derived by dividing the number of cases by the
population of each age group in respective years. In
1997, the annual incidence fell for children 0–4 years
of age, but less for older children 5–14 years of age.
This indicated that the 1997 minor epidemic occurred
mainly in older children, whereas the larger 1996 and
1998 epidemics occurred mostly in younger children.
The median age in each year was 3, 9 and 5 years in
1996, 1997 and 1998, respectively. The median age of
measles cases in 1997 was significantly higher than
that for the 1996 and 1998 epidemics (P! 0–001 for
both comparisons).
Vaccination status of the cases
Vaccination status of the cases by age group is shown
in Figure 6. This status was recorded in MOIF
according to the parental memory or immunization
record if available. The age at vaccination ranged
from 7 to 14 months with a median of 10 months. Of
60 cases under 1 year of age whose vaccination status
and age at vaccination were known, 7 children had
presented measles in the same month of vaccination.
There was no way to know whether these children had
presented with measles within 14 days of vaccination,
during which period the vaccine cannot confer
protection. In the 9–11 months age group, 16 of 39
(41–0%) children, whose vaccination status was
known, had been vaccinated. On average, 79–7% of
measles cases between 1 and 19 years of age had been
previously vaccinated. The PCV by age group is
shown in Figure 6. The age group over 20 years
showed a low PCV, reflecting the fact that the EPI has
been in operation in Malawi for about 15 years.
Vaccine efficacy
PCV was 41–0% (16}39) for the cases aged 9–11
months, and 70–3% (45}64) for those 1 year of age.
Measles vaccination coverage has been reported as
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Fig. 4. Reported measles cases by month. Data are based on the date of onset of rash.
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Fig. 5. Annual incidence of measles by age group.
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Fig. 6. Vaccination status of measles cases by age group. Percentage case vaccinated (PCV) is shown above bars.
67–9% for the former, and 88–3% for the latter age
group in Malawi [12]. These coverage data were
derived from active surveillance and were only
available for the 9–11 and 12–23 months age groups.
Using these data, VE was calculated as 67–3% (95%
CI, 48–3–79–3) and 68–6% (95% CI, 52–7–79–2) for
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Table 1. Proportion of measles cases with specific symptoms or mortality by age group*
Age group Cough Runny nose Red eyes Diarrhoea Pneumonia Death
0 76}80 (95–0) 69}77 (89–6) 64}79 (81–0) 30}78 (38–5) 15}72 (20–8) 1}71 (1–4)
1–4 171}184 (92–9) 164}184 (89–1) 160}185 (86–5) 89}182 (48–9) 38}166 (22–9) 7}166 (4–2)
5–9 152}160 (95–0) 141}158 (89–2) 141}160 (88–1) 71}149 (47–7) 37}140 (26–4) 2}146 (1–4)
10–14 97}106 (91–5) 80}108 (74–1) 103}112 (92–0) 44}99 (44–4) 29}94 (30–9) 1}100 (1–0)
15–19 39}40 (97–5) 32}40 (80–0) 35}40 (87–5) 27}39 (69–2) 9}34 (26–5) 0}35 (0–0)
20› 24}24 (100–0) 20}24 (83–3) 22}24 (91–7) 13}24 (54–2) 10}24 (41–7) 2}24 (8–3)
Total 559}594 (94–1) 506}591 (85–6) 525}600 (87–5) 274}571 (48–0) 138}530 (26–0) 13}542 (2–4)
* Figures in parentheses are percentages.
Cases with missing data were excluded.
Table 2. Relationship between accination and symptoms in measles cases
Cough Runny nose Red eyes Diarrhoea Pneumonia Death
Odds ratio 0–30 0–85 1–32 0–64 0–40 0–34
95% CI 0–09–0–91 0–48–1–49 0–75–2–32 0–44–0–95 0–25–0–62 0–10–1–17
P value 0–030* 0–629 0–360 0–024* ! 0–001* 0–053
* Indicates significant association with vaccination.
 95% CI, 95% confidence interval.
Table 3. Comparison of the proportion with pneumonia between different
age groups with an adjustment for accination history
Comparison Risk v# P value OR 95% CI
Age group Age 20› 3–37 0–067 2–65 0–94–7–49
0 and 20› Vaccination 0–86 0–355 0–56 0–17–1–90
Age group Age 20› 0–58 0–447 1–50 0–53–4–29
1–4 and 20› Vaccination 3–89 0–049* 0–45 0–20–0–99
* Significant at 95% confidence level.
 OR, odds ratio.
 95% CI, 95% confidence interval.
each age group. If the seven cases are excluded who
presented with measles in the same month of
vaccination, assuming that they had got the disease
within 14 days of vaccination, PCV for the 9–11
months group would have been 28–1% and VE 81–6%
(95% CI, 51–8–85–10). Confidence intervals of VE by
the screening method were calculated following
Farrington [13].
Morbidity and mortality
The frequencies of symptoms and mortality are shown
in Table 1. Cases with missing information were
excluded from the analyses. The proportion of cases
with cough, runny nose, and red eyes were not
significantly different among the age groups. The age
group over 20 years showed a significantly higher rate
of pneumonia (41–7%) than for those under 5 years
(P! 0–05).
The relationship between measles vaccination his-
tory and morbidity or mortality is shown in Table 2.
Measles vaccination was negatively associated with
the risk for developing cough, diarrhoea and pneu-
monia. Vaccinated cases tended to show a lower
mortality rate than non-vaccinated, although this did
not reach statistical significance in view of the small
number of deaths.
Table 3 shows a logistic regression analysis for
pneumonia as an outcome comparing two age groups
with adjustment for previous vaccination history. The
age group over 20 years showed no significant
difference in the risk for developing pneumonia
compared with the other age groups, however vac-
cination history was negatively associated with pneu-
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monia in the comparison between the 1–4 and over 20
years age groups.
The overall case fatality rate (CFR) was 2–4%.
CFR in infants was 1–4%, which was not significantly
higher than for the older age groups. CFR in children
under 5 years was 3–4%. The highest CFR was
observed in the age group over 20 years (8–3%). No
significant difference in CFR was shown among the
age groups, possibly because of the small number of
deaths.
The proportion of reported cases without any of the
three symptoms (cough, runny nose and red eyes) was
3–0%. At least two symptoms were present in 93–2%
of the cases (results not shown). The relationship
between mortality and specific symptoms showed
that mortality was significantly associated with diar-
rhoea (v#fl 9–7, P! 0–01) and pneumonia (v#fl 20–8,
P! 0–001) (results not shown).
DISCUSSION
Epidemiology
The surveillance data in this study were reported by
the health facility staff when they identified more than
five measles cases in a week. Not all cases with measles
may have attended the health facilities in Blantyre
District. Thus, there would have been some unreport-
ed cases that were not included in this study. It has
also been reported that patients with rubella are often
misdiagnosed as measles [3]. Therefore, there is no
reason to believe that the diagnosis for measles by the
health facility staff was always accurate. Vaccination
history might not have been confirmed by written
records. Therefore, interpretation of our data should
take into account these limitations which are conse-
quences of the passive surveillance system. However,
we believe that the information obtained by the
MOIF were reasonably reliable because our results
agreed well with previous findings in terms of age
distribution, the negative association of vaccination
history with symptoms, and seasonal trend [14–16].
The age distribution of the cases showed a low but
fairly even distribution between 2 and 12 years of age.
The shift in age distribution of measles cases after the
implementation of mass-immunization was well de-
scribed in the review by Cutts et al. [14]. They
summarized the proportion of reported measles cases
in older children " 5 years as 31–62% for four sub-
Saharan African countries. The proportion for our
sample was 53%, which is comparable to these other
studies. However, they described measles cases which
occurred in older children as mostly among those who
were unvaccinated. In our study, about 80% of cases
between 1 and 19 years of age had been previously
vaccinated. This observation is clearly different from
these previous reports probably because previous
studies were performed in the late 1980s when the EPI
had not been operating for long. In Malawi, where
EPI has been in operation since 1983, a susceptible
population, should have accumulated, because of low
VE, and resulted in a shift of age distribution mostly
among vaccinated children.
However, measles most frequently occurred in
children less than 12 months of age. It is noteworthy
that 34% of the infant cases were between 6 and 8
months. Figure 3 shows that the incidence of measles
increased from 4 months of age, indicating that
Malawian infants start losing maternally acquired
measles antibody around this age. It has been reported
that 12% of infants in Bangladesh maintained a
protective antibody level at 5 months of age, and 5%
at 8 months [17]. Loss of maternal antibody may be
greater in babies born to mothers who are HIV-
seropositive [18], and HIV seropositivity in women of
child-bearing age in Malawi is about 25%. These
observations would support the initial use of measles
vaccine at 6 months of age in this population. AIK-C
measles vaccine strain would be a promising can-
didate, as it has been reported to be effective at 6
months of age in Ghanaian children [19]. It should
also be noted that 59% of the cases between 9 and 11
months with known vaccination history occurred in
non-vaccinated infants (Fig. 6). Thus, it is also
important to strengthen the standard schedule of
vaccination at 9 months of age.
The monthly distribution of measles cases showed
annual epidemics (Fig. 4). The age-group specific
incidence indicated that the second epidemic occurred
mostly in older children (" 4 years), while the pre-
ceding and the subsequent epidemics occurred mainly
in young children (0–4 years) (Fig. 5). This shift
in age groups over consecutive years may indicate
that there is a biennial pattern in the younger age
group and a relatively stable incidence in older age
groups. In the pre-immunization era, measles epide-
mics occurred biennially in England and Wales [16]
and it was possible that virus transmission remained
unchanged following the introduction of the national
measles immunization programme in the United
Kingdom in 1968. Although 3 years of observation
was not enough to conclude that there was a biennial
pattern in the younger age group, this possibility is
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important because it may imply that measles virus
transmission remained unchanged in Malawi during
the study period. After Malawi conducted a mass
vaccination campaign for measles in October 1998,
transmission of the virus would have been affected
significantly [3] thus changing this pattern. It will be
useful to continue to analyse passive surveillance data
from Blantyre to establish the importance of on-going
measles transmission.
Vaccine efficacy
The accuracy of vaccination history is essential in
calculation of VE by the screening method. We could
not trace each case record in health facilities and there
was no way to determine whether the data were based
on written documents. This should be taken into
account in the interpretation of the MOIF. Con-
sidering the negative association between vaccination
history with cough, diarrhoea and pneumonia, which
would be expected, we believe that the data on
vaccination history were reasonably accurate. Based
on vaccination coverage data derived from active
surveillance in Malawi [12], estimated VE was 67–3%
for children aged 9–11 months and 68–6% for children
aged 12–23 months. If we excluded those cases which
presented within the same month of vaccination, PCV
would be 28–1% for the children 9–11 months old and
VE would be 81–6%. Therefore, VE estimates for
children 9–11 months of age ranged between 67–3 and
81–6%. There was no case in the 12–23 months age
group who presented with measles within the same
month of vaccination. VE for this age group was low
at 68–6%. The possible explanation(s) for the low VE
may relate to:
HIV infection
HIV-infected children show a lower seroconversion
rate following measles vaccination [20], and about
6–9% of Malawian children in this area will be HIV-
infected [21].
Interferon
An increased level of interferon in a febrile child may
interfere with the host immune response to vaccine
virus [22]. The WHO recommendation to vaccinate
even mildly febrile children may be justified in these
settings, but could play a role in reducing measles VE.
Waning immunity
Reyes et al. reported one measles case who had
previously shown a documented seroconversion [23].
Their study suggested that measles might occur even
in successfully vaccinated children because of sub-
sequent waning immunity.
Maternal antibody
Transplacentally acquired maternal antibody may
reduce VE, although early loss of passive maternal
antibody in developing countries may reduce the
magnitude of this factor.
Low accine potency
Due to breakdown of the cold chain.
Limitation of MOIF data
The use of MOIF, which only include data where
more than five cases were identified in a week, could
result in lowering the sensitivity for case detection.
This could reduce the precision of the estimate of VE
if the proportion of the vaccinated and non-vaccinated
differ significantly in the unreported cases.
Misdiagnosis
Cases such as rubella may have been misdiagnosed as
measles and this would result in lower specificity for
case definition. This would lead to substantial under-
estimates of VE, as measles vaccine cannot protect
against other diseases.
The screening method provides a simple, rapid and
cheap surveillance tool. Its limitations are that the
proportion of the population vaccinated cannot
usually be tested and detailed analysis of risk factors
for low VE may not be possible [13]. Nevertheless, it
is the basis for deciding whether more methodologi-
cally rigorous investigations are required [11]. Our
figure of 68–6% for the 12–23 months age group
would suggest the necessity for further investigations
such as a cohort or case-control study to confirm the
low measles VE in Malawi.
Morbidity and mortality
Table 2 shows that vaccinated measles cases were less
likely to develop cough, diarrhoea or pneumonia,
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which is consistent with the evidence that vaccinated
children experience milder measles infections [15].
The higher rate of pneumonia in the age group over
20 years compared with those of 1–4 years was
associated with low vaccination coverage in the adult
age group (Table 3), and pneumonia was significantly
associated with mortality (P! 0–001). The highest
mortality rate (8–3%) was also observed in this age
group, although only small numbers were available
for the analysis (Table 1). It is noteworthy that non-
vaccinated adults without past measles infection are at
risk of developing serious measles, for measles in non-
immune adults is severe [24].
The CFR in this study ranged between 0 and 8–3%,
and in children under 5 years it was 3–4%. These rates
might be underestimates because children dying of
measles at home would not have reported to health
facilities. In Niger an overall measles CFR of 2–4%
was reported for children under 5 years in a large-
scale retrospective cohort study (nfl 6919) [4]. Their
infant CFR was 1–5% compared with 1–4% in our
study. This similarity may suggest reasonable re-
liability in the measles surveillance system in Blantyre
District in Malawi.
The MOIF surveillance system was useful to
describe the epidemiology of measles over a 3 year
period for this one district in Malawi. The systematic
analyses of data at the national EPI level is strongly
recommended. A further study is required to confirm
the low VE reported in this study, in order to
facilitate measures to improve VE.
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